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Abstract
Background: Complement promotes neuroinflammation and injury in models of stroke. However, complement is
also being increasingly implicated in repair and regeneration after central nervous system (CNS) injury, and some
complement deficiencies have been shown to provide acute, but not subacute, protection after murine stroke.
Here, we investigate the dual role of complement in injury and repair after cerebral ischemia and reperfusion.
Methods: We used complement-deficient mice and different complement inhibitors in a model of transient middle
cerebral artery occlusion to investigate complement-dependent cellular and molecular changes that occur through
the subacute phase after stroke.
Results: C3 deficiency and site-targeted complement inhibition with either CR2-Crry (inhibits all pathways) or CR2-
fH (inhibits alternative pathway) significantly reduced infarct size, reduced apoptotic cell death, and improved
neurological deficit score in the acute phase after stroke. However, only in CR2-fH-treated mice was there sustained
protection with no evolution of injury in the subacute phase. Whereas both inhibitors significantly reduced
microglia/macrophage activation and astrogliosis in the subacute phase, only CR2-fH improved neurological deficit
and locomotor function, maintained neurogenesis markers, enhanced neuronal migration, and increased VEGF
expression. These findings in CR2-fH-treated mice correlated with improved performance in spatial learning and
passive avoidance tasks. The complement anaphylatoxins have been implicated in repair and regenerative
mechanisms after CNS injury, and in this context CR2-fH significantly reduced, but did not eliminate the generation
of C5a within the brain, unlike CR2-Crry that completely blocked C5a generation. Gene expression profiling revealed
that CR2-fH treatment downregulated genes associated with apoptosis, TGFβ signaling, and neutrophil activation,
and decreased neutrophil infiltration was confirmed by immunohistochemistry. CR2-fH upregulated genes for
neural growth factor and mediators of neurogenesis and neuronal migration. Live animal imaging demonstrated
that following intravenous injection, CR2-fH targeted specifically to the post-ischemic brain, with a tissue half-life of
48.5 h. Finally, unlike C3 deficiency, targeted complement inhibition did not increase susceptibility to lethal post-
stroke infection, an important consideration for stroke patients.
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Conclusions: Ischemic brain tissue-targeted and selective inhibition of alternative complement pathway provide
self-limiting inhibition of complement activation and reduces acute injury while maintaining complement-
dependent recovery mechanisms into the subacute phase after stroke.
Keywords: Ischemic stroke, Complement inhibition, Neuroinflammation, Neuroprotection
Background
Following onset of cerebral ischemia, many stroke pa-
tients show reperfusion of their infarct either spontan-
eously or as a secondary effect of thrombolytic therapy.
Cerebral reperfusion initiates a cascade of pathophysio-
logical events that cause secondary injury, which can
lead to greater tissue damage and more severe functional
and cognitive deficits. Clinical observations and experi-
mental studies indicate a central role for complement
in the propagation of ischemia reperfusion injury (IRI)
in both the central nervous system (CNS) and in non-
CNS tissue [1, 2].
Cumulative evidence indicates that following cerebral
ischemia and reperfusion, complement is activated via
the lectin pathway and amplified via the alternative path-
way (reviewed in [3]). Deficiency or pharmacologic in-
hibition of either pathway is protective in the acute
phase following murine ischemic stroke [4–8]. However,
from a clinical standpoint, it is important to determine
the effect of any potential therapeutic strategy on
longer-term outcome after stroke. While complement
activation may be injurious in the acute phase, there is
evidence that complement also has neuroprotective
functions in the CNS, including after stroke [9, 10]. In
this regard, it has been shown that the protective effect
of lectin pathway deficiency is not sustained in the sub-
acute phase of stroke [11], even though there is a wide
therapeutic window for lectin pathway inhibition and
acute protection [5]. In addition, deficiency in C3, a cen-
tral protein of all complement pathways, provides effect-
ive protection in the acute phase [12, 13], but not the
subacute phase following ischemic stroke [14].
In a previous study, we demonstrated that alternative
pathway-deficient (fB−/−) and inhibited (CR2-fH treated)-
mice are protected from acute injury after cerebral is-
chemia and reperfusion. We further demonstrated that
alternative pathway inhibition resulted in reduced in-
farct volumes and reduced neurological deficit scores in
the subacute phase (7 days) after ischemia [4]. In the
current study, we follow up on this preliminary obser-
vation and investigate how complement modulates the
cellular and molecular events that contribute to post-
stroke degenerative and regenerative processes, and
how this relates to cognitive impairment and functional
recovery. We also investigate whether subacute protec-
tion is a specific property of the alternative pathway.
For this study, we utilize CR2-fH, an inhibitor shown to
specifically inhibit the alternative pathway [15], and
CR2-Crry, an inhibitor of all complement pathways that
has been shown to provide acute protection after
stroke, but that has not been investigated with regard
to subacute outcome [13, 16]. The complement inhibi-
tors Crry and fH are targeted to sites of complement
activation (C3d deposition) via the complement recep-
tor 2 (CR2) moiety [16].
Methods
CR2 fusion proteins
The complement inhibitors CR2-Crry and CR2-fH were
constructed, expressed, and purified as previously de-
scribed [15, 16]. For quality control, complement inhibitory
activity was tested by Zymosan assay as described [17].
Transient ischemic stroke model
Two cohorts of male 8- to 10-week-old wt C57BL/6
mice or C3−/− mice on C57BL/6 background (Jackson
Laboratories) were independently subjected to transient
ischemic stroke, with 60-min middle cerebral artery oc-
clusion (MCAO) [13]. In the first cohort, wt mice re-
ceived one treatment of 0.25 mg CR2-Crry, 0.4 mg
CR2-fH, or 100 μl phosphate buffered saline (PBS) ve-
hicle given intravenously 30 min following reperfusion.
Dosing was based on efficacy titrations performed in a
model of intestinal IRI [15, 16]. Following either 24 h
or 7 days of reperfusion, animals were sacrificed and
brains processed for histology or protein extraction. For
antibiotic prophylaxis, C3−/− mice received 250 mg/L
ciprofloxacin (VetSource) in drinking water ad libitum
14 days prior to MCAO and until sacrifice. In the sec-
ond cohort, wt mice received either one treatment of
0.4 mg CR2-fH or 100 μl PBS vehicle 30 min following
reperfusion. Following either 3 or 7 days of reperfusion,
mice were assessed for neurological outcome as well as
performance on Barnes maze and passive avoidance
tests. Mice were sacrificed on day 7 and brains proc-
essed for histology or protein extraction. Cerebral
blood flow was assessed by Laser Doppler Flowmetry
(Moor Instruments) before, during, and following is-
chemia; mice were excluded if not achieving a reduc-
tion in blood flow to 20 % of pre-ischemia levels.
Temperature, blood pressure, and heart rate were also
monitored before, during, and following ischemia, and
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consistent with previous reports, no differences were
observed [13]. All groups were randomly assigned, and
experimenters were blinded to identity of groups. All ex-
periments and procedures were conducted in accordance
with the Guide for the Care and Use of Laboratory
Animals by the National Institutes of Health and approved
by the Institutional Animal Care and Use Committee at
the Medical University of South Carolina.
Neurological outcomes
Neurological deficit was assessed following MCAO by a
blinded observer using a five-point scoring system, as
previously described [18]. Additionally, locomotor activ-
ity was automatically quantified using the Versamax
open field activity monitor (AccuScan Instruments).
Mice were placed in a random corner and allowed to ac-
climate for 10 min prior to a 60-min testing period. Ex-
ternal noise, lights, and other stimuli were minimized to
reduce bias. Several measures were automatically re-
trieved during the task including total distance moved,
number of movements, time spent at periphery, and
time spent at the center. Activity readings taken prior to
sham procedure were used to establish any differences
in baseline activities. The duration that the animal spent
at the periphery vs. the center was used to assess anxiety
level during the task.
Behavioral testing
Animals of the second cohort were tested for their per-
formance on both Barnes maze and passive avoidance
tasks. To assess spatial reference memory, mice were
trained on Barnes maze for 5 days before surgery, as
previously described [19], then tested again on days 3
and 7 after reperfusion for the time needed to escape
into the hole, the number of error pokes, and the length
of the animal’s path prior to escape. An automated pas-
sive avoidance apparatus (Coulbourn Instruments) was
used to assess avoidance learning with automated sens-
ing and shock systems (GraphicState® 4, Coulbourn
Instruments). The apparatus included a double compart-
ment chamber with one lit and one dark compartment.
Mice were allowed to explore the chamber for 5 min on
habituation phase. Following habituation, the mice were
given one trial where a shock is associated with the dark
side, allowed 48 h of rest, and then tested for retention
measured as latency to enter the dark side. Testing was
repeated on days 3 and 7 post-reperfusion with no shock
delivered during test phase.
Histological and immunohistochemical analysis
For analysis of infarct volume, brains were perfused
transcardially with PBS before their removal, then cut
into 2-mm coronal sections and stained with 2 % triphe-
nyltetrazolium chloride (TTC) [20]. Infarct volumes
were analyzed with ImageJ software (National Institutes
of Health) and calculated as percentage of total brain
from summation of four sections obtained 2 mm apart.
Immunohistochemical staining was conducted on 8-μm
paraffin sections and assessed by a blinded observer by
light microscopy (Olympus BX61). Following antigen re-
trieval (IHC World), the following primary antibodies
were used: anti-ionized calcium-binding adaptor mol-
ecule 1 (Iba-1, 1:250; Abcam), anti-mouse glial fibrillary
acidic protein (GFAP, 1:1000; Dako), anti-von Willibrand
Factor (vWF, 1:500; Dako), anti-Ki67 (1:500; Abcam),
anti-doublecortin (Dcx, 1:200; Millipore), and anti-Gr-1
(1:100, Stem Cell). Primary antibodies were detected
with ImmPress-HRP kit and NovaRed peroxidase chro-
magen (Vector Laboratories), and primary antibodies were
omitted for negative controls. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining was
performed using ApopTag Peroxidase Staining Kit (Milli-
pore) per manufacturer’s instructions. For birth dating
proliferating neuroblasts, intraperitoneal BrdU was ad-
ministered to a subset of mice every other day starting
24 h after reperfusion, and BrdU-positive cells were de-
tected by anti-BrdU antibody (1:300; Sigma).
Quantification of staining
Paraffin sections were obtained +2 to −2 mm relative to
bregma, and sections 200 μm apart were used for quan-
tification. The ischemic core and the penumbra (area
surrounding the ischemic core) were confirmed with
Luxol fast blue staining or counterstaining, and random
fields were examined within the penumbra using an au-
tomated motorized stage on an Olympus BX61 using
Visiopharm software. Counting of apoptotic cells was
performed on an average of eight sections per brain,
with the entire ipsilateral hemisphere being quantified,
and density was calculated as number of positive cells
per square millimeter of tissue. Reactive astrocytes,
microglia/macrophages, and vWF positive vessels were
quantified on sections 200 μm apart. An average of five
sections/brain was quantified. Cells were counted in ran-
domly generated fields, and density was calculated as
number of positive cells per square millimeter of tissue.
Dcx- and Ki67-positive cells were quantified within the
subventricular zone (SVZ) of the lateral ventricles, the
subgranular zone (SGZ) of the dentate gyrus, the basal
ganglia, and the hippocampus from ×40 magnification
random fields on sections 25 to 50 μm apart (three sec-
tions/brain). All analyses were done by light microscopy
(Olympus BX61 with Visiopharm image acquisition soft-
ware) by an observer blinded to the experimental groups.
Tissue protein analysis
Following sacrifice, brains were divided into ipsilateral
and contralateral hemispheres, and protein was
Alawieh et al. Journal of Neuroinflammation  (2015) 12:247 Page 3 of 15
extracted by homogenization in NP-40 lysis buffer
(Invitrogen) containing 1 mm PMSF (Sigma-Aldrich),
92.6 μm FUT175 (BD Biosciences) and 5 μL of protease
inhibitor cocktail (Sigma-Aldrich). Protein concentra-
tions were determined using BCA protein assay kit
(Thermo Scientific). Vascular endothelial growth factor
(VEGF; Abcam), complement C5a (BD Biosciences),
and β-actin (Sigma-Aldrich) were assessed through
Western blotting of 25 μg total protein, with SDS-
PAGE run under reducing conditions, and detected
with HRP-conjugated secondary antibodies (Vector
Laboratories). Signal densities were calculated relative
to β-actin and normalized to wt groups.
Nanostring analysis
Eight C57BL/6 mice (8 weeks of age) were also subjected
to 1 h MCAO and treated with either CR2-fH or PBS
vehicle (n = 4/group) to assess the effect of CR2-fH on
gene expression profile after MCAO. Animals were per-
fused with PBS 72 h after reperfusion, and their brains
were extracted for RNA Extraction. Gene expression
analysis was performed using the Nanostring nCounter
Analysis System (Nanostring Technologies) using a
custom-designed codeset containing 249 genes involved
in immunological and cell survival processes (Additional
file 1) [21]. Each reaction contained 250 ng of total RNA
in a 5-μL aliquot, plus reporter and capture probes, and
six pairs of positive control and eight pairs of negative
control probes. Analysis and normalization of the raw
Nanostring data was conducted using nSolver Analysis
Software v1.1 (Nanostring Technologies). Raw counts
were normalized to levels of reference gene. A back-
ground count level was estimated using the average
count of the eight negative control probes in every reac-
tion plus two SDs.
Animal imaging
Five C57BL/6 mice (8 weeks of age) had their heads
shaved and treated with Nair 2 days prior to MCAO sur-
gery described above. Fluorescently labeled CR2-fH was
injected according to the therapeutic protocol described
above. CR2-fH was labeled using Xenolight C750 NIR
Fluorescent Dye according to manufacturers instructions
(Perkin Elmer). Mice were anesthetized and imaged at 6,
24, 48, 72 and 96 h and at 7 days post-injection using a
Maestro EX imaging system (Perkin Elmer). Sham-
operated animals were also injected as controls. Fluores-
cent signal was quantified with supplied software, and
tissue half-life was calculated according to the formula
t1/2 = t × ln(2)/ln(N0/Nt), where t = fluorescence signal
after time gone by, N0 = signal at beginning (6 h), Nt =
signal after period of time (90 h).
Statistics
Statistical differences between parametric data (infarct
volumes, activity values, ELISA values, cell counts,
densitometry, and Nanostring data) were assessed using
one-way analysis of variance (ANOVA) test with Bonfer-
roni’s multi-group comparison, and non-parametric data
(neurological deficits) were compared with the Kruskal-
Wallis test with Dunn’s comparison (Prism 5.0, Graph-
Pad). Survival was compared from all mice subjected to
MCAO using the Kaplan-Meier test. Differences be-
tween data were considered statistically significant when
p < 0.05.
Results
Targeted complement inhibition reduces the extent of
injury post-MCAO
It has been shown previously that C3 deficiency [12, 13]
or treatment of wt mice with CR2-Crry [16] or CR2-fH
[15] significantly reduces infarct volume 24 h after
MCAO and reperfusion. Here, we investigated the effect
of targeted complement inhibition on subacute injury by
assessing infarct volumes 7 days after MCAO, and com-
pared subacute with acute (24 h) outcomes. Pharmaco-
logical inhibition in all studies reported here was
achieved with a single dose of inhibitor (CR2-Crry or
CR2-fH) administered 90 min after ischemia and 30 min
after reperfusion. Compared to wt control mice, infarct
volume was significantly decreased in C3-deficient mice
and in wt mice treated with either CR2-Crry or CR2-fH
at both 24 h and 7 days post-MCAO (Fig. 1a). At 24 h
after MCAO, there was no significant difference in in-
farct volume between C3-deficient mice and CR2-fH- or
CR2-Crry-treated mice. However, unlike CR2-fH-treated
mice (and wt controls), C3-deficient and CR2-Crry-
treated mice had a rebound increase in infarct volumes
at 7 days compared to 24 h post-MCAO. CR2-fH-
treated mice did not show any significant difference in
infarct volume between the two time points post-
reperfusion. We also assessed cell death in the ipsilateral
cortex, basal ganglia, and hippocampus 7 days following
MCAO using TUNEL staining. CR2-Crry- and CR2-fH-
treated mice showed a significant reduction in cell death
in the basal ganglia and cortex compared to C3−/− and
PBS-treated mice, but only CR2-fH-treated mice had a
significant reduction in hippocampal cell death com-
pared to all other groups. Further, compared to CR2-
Crry-treated mice, CR2-fH-treated mice had significantly
less cell death in the cortex and hippocampus. There
were no significant differences between C3−/− mice and
control mice across the three brain regions (Fig. 1b).
Thus, there is an evolution of secondary injury sub-
acutely after MCAO in C3-deficient mice and CR2-
Crry-treated mice, but not in CR2-fH-treated mice.
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Targeted complement inhibition reduces subacute
microglia/macrophage activation and astrogliosis after
MCAO
Microglia and astrocytes become activated in response
to pathological changes, and microglia/macrophage acti-
vation and astrogliosis mark inflammation within the
CNS, which is reduced at 24 h after MCAO by comple-
ment inhibition [4]. Microglia/macrophage activation
and astrogliosis in the subacute phase at 7 days post-
MCAO was assessed by immunohistochemical detection
of Iba-1 and GFAP markers in the striatum, respectively.
Compared to wt controls, there was a significant reduc-
tion in both activated microglia/macrophages and react-
ive astrocytes in CR2-Crry- and CR2-fH-treated mice
(Fig. 2). In contrast, there was no significant difference
in the detection of either marker in C3-deficient mice
compared to wt. No differences were observed in the
contralateral hemispheres between groups. These data
indicate that C3 inhibition, but not C3 deficiency, reduce
glial cell activation in the subacute phase after MCAO.
Effect of complement inhibition on neurological outcome
and locomotor function after MCAO
We next determined whether the reduced injury and in-
flammation seen in complement-inhibited mice trans-
lated into improvement in neurological outcome after
MCAO. Both CR2-Crry and CR2-fH have been shown to
improve neurological deficits 24 h after MCAO [4, 13],
and here, we used the same deficit scoring method to as-
sess neurological outcome over a 1-week period post-
MCAO. Compared to wt controls, C3 deficiency and
treatment with either CR2-Crry or CR2-fH significantly
improved neurological deficit scores up to 72 h post-
MCAO (Fig. 3a). However, only CR2-fH-treated mice
continued to display significantly improved neuro-
logical deficit scores at 7 days post-MCAO.
To more objectively assess neurological deficit, we
measured locomotor activity using an open field activity
monitor. There was no significant difference in loco-
motor activity between any group up to 3 days post-
MCAO, but on day 7, CR2-fH-treated mice had signifi-
cantly increased locomotor activity compared to all
other groups (Fig. 3b, c). Since a difference in anxiety
levels may confound performance on open field as well
as other tasks, we also assessed anxiety levels across the
groups by measuring the percentage of time spent at the
center of an open field. We found no significant differ-
ences in anxiety levels among the different groups on
days 3 and 7 post-MCAO (Fig. 3d). The picture emer-
ging from the data thus far indicates that in the subacute
phase after stroke, CR2-fH provides better protection
than CR2-Crry or C3−/− in terms of evolution of sec-
ondary injury and neurological outcome.
CR2-fH maintains neurogenesis and enhances neuronal
migration in the subacute phase after MCAO
Since complement activation products have been impli-
cated in ischemia-induced neurogenesis that contributes
to recovery, we investigated the effect of complement in-
hibition on proliferation and neurogenesis in the brain
after MCAO. Immunostaining for the proliferation
marker Ki-67 was performed on sections from the sub-
ventricular zone (SVZ) of the lateral ventricles and the
subgranular zone (SGZ) of the dentate gyrus, neuro-
genic niches of the adult brain previously studied in the
context of ischemia-induced neurogenesis [22–24]. C3-
deficient and CR2-Crry-treated mice, but not CR2-fH-
treated mice, had a significant reduction in numbers of
proliferating cells within the ipsilateral SVZ compared
to wt controls, indicating that, unlike total complement
blockade, alternative pathway blockade does not inhibit
ischemia-induced neurogenesis (Fig. 4a). No differences
were observed between any group in the ipsilateral
Fig. 1 Complement inhibition reduces cerebral injury and cell death following MCAO and 7 days reperfusion. a Infarct volumes after 60 min MCAO
and either 24-h or 7 days reperfusion. Mean +/− SEM, n = 8–12 mice. **p < 0.01, ***p < 0.001, #p < 0.001. b Cell death in different brain regions as
analyzed by TUNEL immunostaining at 7 days after MCAO. Mean +/− SEM (TUNEL-positive cells per square millimeter), n = 5–6 mice. *p < 0.05
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SGZ (Fig. 4b), or in contralateral regions (data not
shown). Immunostaining for doublecortin (Dcx), an-
other marker of neurogenesis that is expressed by imma-
ture neurons (neuroblasts), similarly showed a higher
number of Dcx-positive cells in the ipsilateral SVZ of
CR2-fH-treated mice compared to CR2-Crry-treated mice
or C3-deficient mice (Fig. 4c, d). No differences in num-
bers of Dcx-positive cells were observed between any
group in the contralateral SVZ (data not shown). Since
CR2-fH treatment did not significantly increase neurogen-
esis compared to wt mice at 7 days post-MCAO, we fur-
ther investigated a potential effect of CR2-fH on neuronal
migration by quantifying the number of Dcx-positive cells
in the ipsilateral basal ganglia and hippocampus of mice
post-MCAO; CR2-fH treatment significantly increased
neuroblastic cell migration from the SVG to the basal gan-
glia (Fig. 5a, b) and hippocampus at 7 days after injury
(Fig. 5c, d).
CR2-fH less effectively blocks complement activation than
CR2-Crry
Complement activation products, specifically C3a and/or
C5a, have been implicated in promoting neuroregenera-
tion after CNS injury. Therefore, since CR2-Crry inhibits
all complement pathways and CR2-fH inhibits only the
alternative pathway, a quantitative difference in the level
of complement activation is one potential mechanism
that could account for the different subacute outcomes
and difference in SVZ neurogenesis. To assess this, we
measured C5a levels in the ipsilateral hemisphere of
mice on days 1, 3, and 7 after MCAO (Fig. 6). Compared
to controls, CR2-fH significantly inhibited C5a gener-
ation when measured at 1 and 3 days after MCAO, but
to a lesser extent than CR2-Crry, which almost com-
pletely blocked C5a generation. No differences in C5a
levels were detected across the groups on day 7. This re-
sult is consistent with CR2-fH providing sufficient
Fig. 2 Complement inhibition reduces microglia/macrophage activation and astrogliosis following MCAO and 7 days reperfusion. a Representative
images of activated microglia/macrophages as assessed by Iba-1 immunohistochemical detection across the different groups. Scale bar = 200 μm. b
Quantification of Iba-1 immunohistochemical staining. Mean +/− SEM (positive cells per square millimeter), n = 6–8 mice. *p < 0.05, **p < 0.01.
c Quantification of reactive astrocytes as assessed by GFAP immunohistochemical detection. Mean +/− SEM (positive cells per square millimeter), n =
5–7 mice. *p < 0.05
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complement inhibition to provide protection from injury
in the acute phase, while allowing for lectin and/or clas-
sical pathway generation of complement activation prod-
ucts at a level sufficient for promoting recovery and
neurogenesis in the subacute phase.
Profiling of gene expression changes after CR2-fH
treatment.
Due to the improved subacute outcomes observed with
CR2-fH treatment compared to CR2-Crry treatment of
C3 deficiency, we further investigated the effect of CR2-
fH treatment by analysis of gene expression profiles
3 days after MCAO. We used Nanostring analysis for
high-sensitive capture of mRNA transcripts among a
panel of 248 genes involved in immunological, inflam-
matory, and cell death processes (see Additional file 1
for full list). Among the identified hits of genes exhibit-
ing a significant difference between CR2-fH-treated and
wt groups (Additional file 1), genes whose expression
showed more than 25 % increase or decrease are shown
in Fig. 7a, b. Apoptotic markers (Bax, Atf4), components
of TGFβ signaling (TGFβ 2, BMP2, Smad3), and markers
of neutrophil activation (Gr-1, MMP9) were among the
downregulated genes, which is line with our findings of
reduced inflammatory cell activation and apoptosis in
mice treated with CR2-fH. On the other hand, neuronal
growth factor (NGF) and two key mediators of neuro-
genesis and neuronal migration, VEGF and NCAM,
previously reported to exhibit increased expression in
migrating neuroblasts [25, 26], were among the signifi-
cantly upregulated genes.
CR2-fH increases subacute VEGF levels in the brain after
MCAO
Since VEGF plays an important role in angiogenesis as
well as neuroblast proliferation and migration following
ischemia [25], we assessed VEGF levels in the ipsilateral
hemisphere 7 days after MCAO. CR2-fH-treated mice
had significantly increased levels of VEGF 7 days after
MCAO compared to both wt controls and CR2-Crry-
treated mice (Fig. 8a, b). Immunostaining for von Willi-
brand factor (vWF), however, did not reveal any differ-
ences in vessel density between the groups at 7 days
post-MCAO (Fig. 8c). While it is possible that alterna-
tive pathway inhibition with CR2-fH may promote post-
ischemia neurogenesis by increasing VEGF levels, it does
not appear to have any effect on angiogenesis in the sub-
acute phase. These data support the above Nanostring
data and further implicate VEGF in the observed CR2-
fH-dependent increase in neuroblast proliferation and
migration.
CR2-fH improves spatial reference memory and avoidance
learning in the subacute phase after stroke
Based on the significant sparing of hippocampal damage
and increased neuroblast migration resulting from CR2-
Fig. 3 Effect of complement inhibition on behavioral deficit and locomotor function after MCAO. a Neurological deficit scores (0–4) within the first
week after MCAO. Mean +/− SEM, n = 8–13. One-way ANOVA, **p < 0.05 (wild-type compared to all other groups), *p < 0.05 (wild-type compared to
CR2-fH only). b Anxiety assessment across the different groups measured as percent time spent at the center of an open field. Mean +/− SEM.
(One-way ANOVA, n.s. p > 0.05). c, d Locomotor activity measured as total distance moved (c) or number of movements (d), using an open
field activity monitor. Determinations were made 2, 3, and 7 days after MCAO. Mean +/− SEM, n = 8–13. One-way ANOVA, *p < 0.05(CR2-fH-
treated compared to wild-type)
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Fig. 5 CR2-fH increases neuroblasts migration to perilesional basal ganglia and hippocampus at 7 days post-MCAO. a Representative images of
neuroblast migration to the basal ganglia. b Quantification of number of Dcx + cells in basal ganglia. Bar = Mean +/− SEM, n = 5. *p < 0.05. c
Representative images of neuroblasts in the hippocampus. d Quantification of number of Dcx + cells in hippocampus. Bar = Mean +/− SEM,
n = 5–6. *p < 0.05
Fig. 4 CR2-fH increases subventricular zone neuronal proliferation and neuroblast presence at 7 days post-MCAO. a Doublecortin (Dcx+) neuroblasts
within the ipsilateral SVZ at 7 days post-MCAO. Bar = Mean, n = 5–7. b Ki-67+ proliferating cells within the ipsilateral subventricular zone (SVZ)
of the lateral ventricles. Bar = Mean. c, the subgranular zone (SGZ) of the dentate gyrus. Bar = Mean (density calculated from five random HPF),
n = 3–7. *p < 0.05. d Representative images of immunostained sections, ×20 magnification. Scale bar = 150 μm. e Representative immunofluorescence
double staining of SVG in CR2-fH-treated mice with anti-BrdU (green) and anti-Dcx (red), showing co-localization of signal
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fH treatment, we performed a more detailed investiga-
tion of cognitive outcome by analysis of spatial reference
memory and avoidance learning using Barnes maze and
passive avoidance tasks. On passive avoidance task, there
were no significant differences between wt controls and
CR2-fH-treated mice 3 days post-MCAO, with mice from
both groups recording latency to enter times similar to
the times that were recorded pre-surgery (Fig. 9a). How-
ever, on day 7 post-MCAO, there was a significant deteri-
oration in performance of the wt control group, whereas
the performance of CR2-fH-treated mice was not signifi-
cantly different to that recorded pre-surgery.
On Barnes Maze task 3 days post-MCAO, the per-
formance of wt control mice deteriorated significantly,
Fig. 6 Different levels of C5a generation in brains from CR2-fH- and CR2-Crry-treated mice through subacute phase after stroke. a Relative C5a
expression as determined by density scan of Western blot of ipsilateral brain tissue extract. Shown are relative expression levels normalized to
level in wt control mice at 24 h. Mean +/− SEM, n = 4 animals per group, *p < 0.05. b Representative Western blot for C5a in brain homogenate
Fig. 7 Nanostring analysis of changes in mRNA expression profile secondary to CR2-fH treatment at 7 days post-MCAO. a Genes with significantly
reduced expression after CR2-fH treatment that exhibit more than 0.8-fold reduction in expression levels. Levels are normalized to the Mean of
the wt controls. Mean +/− SEM, n = 4, *p < 0.05. b Genes with significantly increased expression after CR2-fH treatment that exhibit more than
1.25-fold reduction in expression levels. Levels are normalized to the Mean of the wt controls. Mean +/− SEM, n = 4, *p < 0.05. A complete dataset
of different analyzed transcripts is provided in Additional file 1
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as manifested by an increase in latency to escape, path
length, and number of error pokes compared to pre-
surgical baseline. By day 7 post-MCAO, performance of
this group was improved, but was still significantly
worse compared to pre-surgical baseline (p < 0.05). In
contrast, CR2-fH-treated mice displayed no impairment
on Barnes maze performance at either 3 or 7 days post-
MCAO compared to pre-surgical baseline (Fig. 9b–d).
Thus, compared to wt controls, CR2-fH treatment
significantly improved spatial reference memory
through the subacute phase after ischemic stroke.
To control for possible cognitive-enhancing effects of
CR2-fH, we also treated sham-operated mice with CR2-
fH and tested cognitive performance after sham surgery
on both tasks. CR2-fH treatment did not enhance cog-
nitive performance in sham-operated mice (Fig. 9). The
above data together show that a single post-reperfusion
dose of CR2-fH not only improves neurological/locomotor
Fig. 8 CR2-fH increases relative VEGF expression but not angiogenesis in the ipsilateral brain at 7 days post-MCAO. a VEGF expression as determined
by Western blot analysis of ipsilateral brain tissue extract. Shown are relative expression levels normalized to level in wt control mice, with
β-actin serving as a loading control. Bar =Median, n = 4, *p < 0.05. b Representative Western blot for analysis of VEGF expression. c Von Willibrand
factor positive (vWF+) vessels within the ipsilateral brain as detected by immunohistochemistry. Bar =Median (positive vessels per ten high-powered
fields), n = 6
Fig. 9 CR2-fH improves cognitive performance 7 days post-MCAO. a CR2-fH improves performance on passive avoidance task 7 days after MCAO.
Shown is latency to enter a dark box associated with a shock. Mice were given a trial to associate a shock with the dark side of an apparatus, and
latency to enter dark side was evaluated on days 3 and 7 post-MCAO. Mean +/− SEM, n = 7–10, *p < 0.05. b–d, CR2-fH reduces spatial memory
deficits in Barnes maze task in the subacute phase after MCAO. Mice were trained on the maze for 5 days before surgery and then tested on days
3 and 7 after MCAO for latency to escape (b), path length (c), and number of error pokes (d). Mean +/− SEM, n = 9–10, *p < 0.05, **p < 0.01
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and histological measures in the subacute phase after
stroke, but also improves cognitive performance.
CR2-fH treatment reduces neutrophil infiltration into the
brain after MCAO
Data from Nanostring analysis showed a downregulation
in markers of neutrophil activation after MCAO and
CR2-fH treatment, and we therefore examined neuronal
infiltration by staining sections with the neutrophil
marker Gr-1. Compared to wt, CR2-fH treatment re-
sulted in a significant (threefold) reduction in the num-
ber of Gr-1-positive cells, suggesting a significant
reduction in neutrophil infiltration into the parenchyma
(Fig. 10a, b). These data supplement the data above
showing a significant reduction in the activation of resi-
dent inflammatory cells in the brain after CR2-fH
treatment.
Acutely administered CR2-fH targets to the post-ischemic
brain and persists into the subacute phase after stroke
We have previously demonstrated C3d-specific binding
of CR2-fH [15], and to investigate C3d deposition and
the targeting and retention of CR2-fH in the post-
ischemic brain, we performed in vivo fluorescence im-
aging. Fluorescently labeled CR2-fH was administered
according to our therapeutic protocol, and shaved heads
of mice (hair removed to prevent signal interference)
were imaged over a 7-day period post-reperfusion. Tar-
geting and localization of CR2-fH was clearly evident
6 h after reperfusion, with a gradual decline to near un-
detectable levels in live animals by 7 days (Fig. 11a, b).
The calculated tissue half-life based on fluorescence sig-
nal was 48.5 h. No fluorescence was detected in the
brains of sham-operated animals at any time point (not
shown). Although fluorescent signal was barely detect-
able in live animals 7 days after MCAO, ex vivo imaging
of the brain removed after sacrifice on day 7 demon-
strated the continued presence of labeled CR2-fH, with
localization to the ipsilateral parenchyma (Fig. 11c).
Complement inhibition does not increase post-stroke
mortality
Immunosuppression and associated complications such
as pneumonia are a major concern in stroke patients,
and are a frequent cause of morbidity and mortality both
clinically [27, 28] and in the experimental model used
here [29]. As complement plays an important role in
host defense, we determined whether treatment with
CR2-Crry or CR2-fH affects animal survival in our
model. Neither inhibitor significantly affected 7-day sur-
vival compared to control-treated animals (Fig. 12). On
the other hand, C3-deficient mice had significantly re-
duced 7-day survival compared to mice receiving in-
hibitor treatment. To investigate whether increased
mortality in C3-deficient mice may be due to compro-
mised host defense, we treated C3-deficient mice with
antibiotics for 2 weeks prior to MCAO and for 7 days
post-reperfusion. Antibiotic treatment reversed the ef-
fect of C3 deficiency on animal survival, with survival
rates the same as for CR2-fH-treated mice. These data
indicate that CR2-fH treatment does not compromise
complement-dependent host defense mechanisms and
increase susceptibility to secondary infectious compli-
cations following experimental ischemic stroke.
Discussion
Complement-mediated inflammation has been shown to
play an important role in the progressive degenerative
events that take place after ischemic stroke, but there is
increasing evidence that complement is also involved in
subsequent repair and regenerative mechanisms that
occur during recovery [3]. Numerous studies have shown
Fig. 10 CR2-fH reduces brain neutrophil infiltration at 7 days after MCAO. a Representative images of neutrophil infiltration assessed by
immunohistochemical staining with anti-Gr-1 antibody. Scale bar = 50 μm. b Quantification of Gr-1+ cells using 10 HPF/brain. Bar =Mean +/−
SEM, n = 5, *p < 0.05
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that complement deficiency or inhibition is protective in
the acute phase after stroke (24–48 h), but it has also been
shown that complement deficiency can worsen subacute
outcomes [11, 14]. The reasons for the differences in acute
and subacute outcomes are not well understood, but it is
clear that complement has a balancing role in injury vs.
protection in many pathological conditions, and differ-
ences in acute and subacute outcomes after stroke may be
due to balancing roles for complement in early inflamma-
tion and injury vs. subsequent neuroprotection and neuro-
genesis. In the context of neuroprotective functions of
complement, both C3a and C5a have been shown to be
protective against excitotoxic neuronal injury [30–32],
and C3a has a protective role in neonatal hypoxia-
ischemia brain injury [33], even though C1q exacerbates
injury in a similar model [34]. C3a is also implicated in
promoting neurogenesis, both basal [14] and following is-
chemic stroke [34], and similar to C5a, it has been shown
to regulate the differentiation and migration of neural pro-
genitor cells in vitro [35, 36]. In addition, complement op-
sonins of the classical (C1q), lectin (MBL, ficolins), and
alternative (properdin) pathways, as well as C3 opsonins
common to all pathways, promote the clearance of apop-
totic cells and debris, which is important for the resolution
of inflammation and recovery [35, 37, 38].
The data presented here support the notion of a dual
role for complement in ischemic stroke by comparing
C3 deficiency with transient approaches of complement
inhibition using CR2-Crry and CR2-fH (Fig. 13). We
demonstrate that whereas C3 deficiency and comple-
ment inhibition provides acute protection after ischemic
stroke, only complement inhibition reduces inflamma-
tion and cell death in the subacute phase, and only in-
hibition of the alternative pathway with CR2-fH
prevents evolution and spread of injury. The transient
nature of complement inhibition provides an explan-
ation for the worse subacute outcomes in complement-
deficient vs. complement-inhibited mice. Complement
deficiency will prevent the early pro-apoptotic and pro-
inflammatory effects of complement mediated by the
anaphylatoxins and opsonins that trigger complement-
dependent phagocytosis, an effect that is also achieved
by complement inhibition. However, complement inhib-
ition will allow for recovery of complement function at
the subacute phase permitting for critical neuro-
reparatory functions of the complement system that
Fig. 11 CR2-fH localizes to the brain after MCAO and specifically targets the ipsilateral lesion site. Fluorescently labeled CR2-fH was administered
as described for therapeutic protocol, and localization of CR2-fH was visualized by in vivo fluorescence tomography. a Representative images of
head scans of a single mouse taken at indicated times. b Quantification of fluorescent signal. Mean +/− SEM, n = 5 (24–72 h), n = 4 (72 h), n = 3 (7
days). c, Ex vivo image of brain removed 7 days after MCAO and injection of labeled CR2-fH (lower) or PBS (upper)
Fig. 12 CR2-fH and CR2-Crry treatment but not C3 deficiency improves
survival at 7 days post-MCAO. Kaplan-Meier survival analysis of C3-
deficient or complement inhibitor-treated mice over a 7-day period
post-MCAO. One group of C3-deficient mice received antibiotic
prophylaxis (C3 −/− + Anti), n = 19–33, *p < 0.05
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involve promoting neurogenesis, clearance of debris and
resolution of inflammation. To support this hypothesis,
we analyzed the temporal profile of CR2-fH in the brain
after a single injection and demonstrated targeted post-
ischemic binding with diminishing levels during progres-
sion to the subacute phase, which would presumably
allow complement-mediated homeostatic and neuropro-
tective mechanisms to become operable as inflammation
is resolved.
The use of two different complement inhibitors in this
study allowed us to investigate the selective contribution
of the alternative complement pathway in secondary in-
jury after stroke. Of the two complement inhibitors in-
vestigated, only CR2-fH improved neurological deficit
and locomotor function at 7 days after stroke. Improved
motor outcome at 7 days in CR2-fH-treated mice com-
pared to CR2-Crry-treated mice and C3-deficient mice
is associated with significantly lower cortical cell death
in the CR2-fH-treated group. In addition, only CR2-fH-
treated mice had significantly reduced hippocampal cell
death, and only CR2-fH-treated mice did not display a
reduction in neurogenesis markers in the SVZ. In
addition to maintaining post-stroke neurogenesis, CR2-
fH treatment also promoted significantly more neuro-
blast migration from the SVG compared to wt mice,
findings that correlated with improved performance on
spatial learning and passive avoidance tasks in the sub-
acute phase after stroke. Since complement activation
products are implicated in acute injury as well as recov-
ery and neurogenesis after CNS injury, a mechanism
accounting for the different subacute outcomes in CR2-
fH- vs. CR2-Crry-treated mice may be related to a dif-
ference in the extent of complement activation. Current
evidence indicates that following cerebral ischemia and
reperfusion, complement is activated by the lectin path-
way [5–9] and amplified by the alternative pathway [4].
As outlined above, C3a and C5a have neuroprotective/
regenerative roles, and whereas CR2-fH treatment sig-
nificantly inhibited C5a generation in the ipsilateral
brain for up to 3 days after stroke, C5a levels were still
significantly higher than in brains from CR2-Crry-
treated mice. Thus, CR2-fH maintains a baseline level
of C5a generation through the subacute phase that cor-
relates with improved overall post-stroke recovery, and
based on previous data, this likely occurs via the lectin
pathway. Differences in the extent of complement acti-
vation could also account for our observations that
CR2-Crry is more effective than CR2-fH at reducing
acute injury (lesion size), even though longer-term out-
comes are worse. The concept of CR2-fH providing op-
timal longer-term protection by self-limited complement
activation is further supported by findings that high-dose,
but not low-dose, C3aR antagonism impaired post-stroke
SVZ neurogenesis in the subacute phase [14, 24]. CR2-fH,
but not CR2-Crry, also increased VEGF expression within
the ipsilateral hemisphere, and this may point to an-
other protective mechanism of CR2-fH. Although the
role of complement in post-stroke angiogenesis has not
been investigated, C3a and C5a have been shown to
promote VEGF expression and pathogenic neovascular-
ization within the retina in a model of age-related
macular degeneration [39]. We did not observe differ-
ences in angiogenesis with complement inhibition, but
it is possible that this may occur at later time points.
Regarding post-stroke neurogenesis, findings are mixed
on whether newly forming neurons make a functional im-
pact on plasticity and recovery. Here, we investigated
neurogenesis and neuroblast migration 7 days following
ischemic stroke, and show that increased neuroblast
migration to the basal ganglia and hippocampal area in
CR2-fH-treated mice is indeed associated with im-
proved performance on cognitive and memory tasks.
The effect of CR2-fH on neurogenesis and neuroblast
migration was also associated with increased levels of
NCAM and VEGF transcript and VEGF protein. Both
molecules have been studied in the context of neurode-
velopment, with VEGF expression shown to induce
neuroblast proliferation and migration, while NCAM is
a neuronal adhesion molecule essential for the forma-
tion of chains of migrating neuroblasts during
Fig. 13 Schematic depicting complement activation and the effects of CR2-Crry vs. CR2-fH on complement-dependent effector mechanisms after
ischemic stroke
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development [26] It is noteworthy that CR2 expression
in neural progenitor cells has been shown to regulate
hippocampal neurogenesis, and treatment with the CR2
ligand, C3d, was shown to reduce the number of prolif-
erating neuroblasts in vivo [40]. It is therefore possible
that the CR2 targeting moiety of CR2-fH could be con-
tributing to its function by competing with the inter-
action of C3d with CR2 expressed on neural progenitor
cells, although it is unlikely this represents a principle
mechanism of action since there is inhibition of neuro-
genesis in CR2-Crry-treated mice compared to wt.
The C3a and C5a anaphylatoxins are implicated in
promoting immune cell migration and infiltration, and
may also be involved in neuroblast migration. Interest-
ingly, however, while we show that the significant reduc-
tion of C5a levels in the brains of CR2-fH-treated mice
is associated with decreased immune cell infiltration
(especially neutrophils), it is associated with enhanced
neuroblast migration. CR2-fH inhibited but did not
completely block C5a generation, and there may be dif-
ferent thresholds for anaphylatoxin stimulation or dif-
ferent mechanisms of action of the anaphylatoxins in
immune cell vs. neuroblast migration, and these data
again highlight the dual role of complement in injury
and repair.
Additional differences between C3-deficient and
complement-inhibited mice were the extent of microglial
activation and post-stroke mortality. C3-deficient mice
had significantly higher activation of microglial/macro-
phage cells compared to complement-inhibited mice.
The reason for the higher levels of microglial/macro-
phage activation in C3-deficient mice is not clear, but
may be related to the increased levels of striatal apop-
tosis found in complement-deficient vs. inhibited mice.
In this regard, C3 opsonization of apoptotic cells is
known to play a role in apoptotic cell clearance, and the
complete absence of this process in C3-deficient mice
may more severely restrict cell clearance and impair the
resolution of inflammation. In addition, C3-deficient
mice had a significantly higher mortality rate compared
to complement-inhibited mice. Treatment of C3-
deficient mice with an antibiotic eliminated this differ-
ence, indicating that increased mortality was due to in-
fection. Complement plays an important role in host
defense mechanisms, and our finding here is also in ac-
cord with a previous study in which it was shown that
C3 deficiency, but not CR2-Crry treatment, increased
susceptibility to infection in a model of septic peritonitis
[16]. CR2-mediated targeting obviates the need for sys-
temic complement inhibition [15, 16], and the current
data indicate that CR2-fH does not increase susceptibil-
ity to infection following experimental ischemic stroke.
Secondary infectious complications are a serious con-
cern for stroke patients, and infection (septicemia and
pneumonia) is a major cause of death following stroke in
the model we use here [29]. Other known causes of
mortality after stroke include hemorrhagic transform-
ation, brain edema and, with regard to experimental
stroke, loss of mobility leading to malnutrition and dehy-
dration of the animal.
Conclusions
In conclusion, we show that an acutely administered
dose of CR2-fH reduced injury and improved neuro-
logical and behavioral outcomes in the subacute phase
after stroke. These improved outcomes were linked to
reduced extent of cell death and increased neurogenesis
and VEGF expression. The improved longer-term out-
comes in CR2-fH-treated mice compared to CR2-Crry-
treated and C3-deficient mice, and the inhibition of
neurogenesis in CR2-Crry-treated and C3-deficient mice,
indicate that CR2-fH provides targeted and self-limiting
complement inhibition that dissects the dual role of
complement in injury and recovery after stroke. This
conclusion is supported by data showing that CR2-Crry
more completely blocks complement activation than
CR2-fH, as determined by comparing post-stroke brain
levels of the complement activation product, C5a. This
approach of alternative pathway inhibition offers poten-
tial advantages over systemic and/or regulated doses of
complement inhibitors that may be contraindicative to
long-term outcome. The current findings also warrant
further investigation into therapeutically relevant issues
such post-stroke therapeutic window, outcomes in older
mice with increased stroke risk factors or with pre-
existing cerebrovascular disease, and outcomes in pre-
and post-menopausal female mice.
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